Corifollitropin Alfa Followed by Menotropin for Poor Ovarian Responders Trial
Status:
Completed
Trial end date:
2016-05-01
Target enrollment:
Participant gender:
Summary
In combination with the existing literature, previous work indicates that 1) women with poor
ovarian response fulfilling the "Bologna criteria" have very low pregnancy rates,
irrespective of age 2) current treatment protocols demonstrate ongoing pregnancy rates that
do not exceed 8.5% and 3) corifollitropin alfa followed by hpHMG might increase ongoing
pregnancy rates in young patients (<40years old) fulfilling the criteria. These findings
provide a strong rationale for a definitive large RCT. The COMPORT study will provide
conclusive evidence regarding the superiority or not of this novel protocol with
corifollitropin alfa followed by hpHMG for the treatment of young poor ovarian responders
fulfilling the Bologna criteria.
Phase:
Phase 3
Details
Lead Sponsor:
Universitair Ziekenhuis Brussel
Collaborators:
Ho Chi Minh City University of Medicine and Pharmacy University of Medicine and Pharmacy at Ho Chi Minh City